The incudomalleal and incudostapedial articulations are synovial joints that may be involved in the inflammatory process in patients with juvenile idiophathic arthritis (JIA). The aim of the study was to assess the frequency of hearing impairment and associated risk factors in JIA patients.

Pain is a neuroimmune condition in which immune cells interact with the somatosensory system, contributing not only in the initiation and sensitization of pain but also in its resolution. This review aims to decipher the immunological pathways implicated in pain, illustrating how immune cells and mediators contribute to pain persistance and examining new therapeutic prospects.

To establish French recommendations for the management of people living with hand osteoarthritis (OA) on behalf of the French Society of Rheumatology (SFR) and of the French Society of Physical and Rehabilitation Medicine (SOFMER).

Intra-articular injections of platelet-rich plasma (PRP) are increasingly utilized in the management of knee osteoarthritis (KOA) and various other medical specialties. However, the efficacy of PRP remains a contentious issue; some experts consider it to be a placebo, while others advocate for its therapeutic value. Evidence from controlled clinical trials and meta-analyses has often yielded contradictory results, frequently failing to demonstrate a clear clinical benefit despite favorable outcomes observed in real-world settings. Several factors may contribute to these inconsistencies, with the lack of standardization in PRP preparation and the heterogeneity of KOA phenotypes being the most significant. Phenotyping is more effectively accomplished in specialized clinical environments, which may elucidate the improved outcomes associated with better patient selection. After delineating the specific characteristics of PRP injections and the primary sources of variability, we emphasize the necessity for comprehensive characterization of the injected product and accurate phenotyping of KOA. Additionally, we examine the methodological biases that impede the interpretation of clinical results and propose a treat-to-target approach as a more suitable evaluation strategy. These methodological challenges should not undermine the potential of regenerative medicine, which offers considerable promise. Compared to conventional therapies, regenerative medicine is generally more compatible with human physiology, better tolerated, and potentially less expensive. However, the advancement of this field necessitates strict scientific rigor and objectivity. This involves a meticulous recognition of biases and methodological limitations, as well as a deeper understanding of the underlying mechanisms of action, to refine and optimize therapeutic protocols.

Stroke is the leading cause of acquired physical disability. In recent years, there has been a decline in early mortality due to acute medical care as well as better and earlier prevention of adverse events after stroke, therefore exposing more these patients to fragility fractures. We report very early assessment of bone microarchitecture changes in the first months following stroke-induced hemiplegia in a monocentric prospective study.

Axial spondyloarthritis has undergone major changes since the turn of the century, concerning terminology (from ankylosing spondylitis to radiographic axial spondyloarthritis), classification criteria, introduction of targeted therapies (anti-TNF, anti-IL17, JAK inhibitors), and management strategies. Epidemiological data indicate an increasing incidence and a shorter diagnostic delay. Over the past 25 years, additional modifications have been observed: recognition of non-radiographic forms (up to 50% in recent studies), lower male predominance with a sex ratio tending to parity, reduced frequency of HLA-B27 and uveitis, wider use of targeted treatments, and changes in treatment response profiles. Overall disease severity appears to be reduced according to several indicators, including mortality, hip involvement, structural progression, and amyloidosis. The determinants of these changes remain debated and discussed in this narrative review, in the absence of long-term longitudinal studies and because of limited comparability across different time periods. The impact of environmental factors still needs to be assessed.

The objective of this scoping review was to identify the factors that are associated with the negative consequences of OA (hip, knee and hand OA) on employment.

To determine the prevalence of neuropathic-like pain (NP) in people with hand osteoarthritis (HOA), and to compare the demographic and clinical characteristics of HOA patients who experience NP with those who do not.

The primary objective of the study was to demonstrate the superiority of platelet-rich plasma injections in treating facet joint syndrome, compared to corticosteroid injections. Secondary objectives were to assess the efficacy of PRP compared to CTC on pain, functional impact, tolerance, and healthcare utilization following the initial infiltrative management.

Janus kinase (JAK) inhibitors are effective treatments for autoimmune rheumatic diseases (AIRDs). However, concomitant use of JAK inhibitors with CYP enzyme inhibitors or OAT3 inhibitors can lead to drug-drug interactions. This study aimed to evaluate the impact of the concomitant use of CYP and OAT3 inhibitors on discontinuation of treatment and infectious complications in patients treated with JAK inhibitors.

We performed next generation sequencing in two affected-sibling pairs of atypical femur fractures (AFF) and in unrelated cases of AFF to identify genetic variants of bisphosphonates (BP)-associated AFF.

Gout, one of the most prevalent inflammatory arthropathies, arises from hyperuricemia and is increasingly recognized as a condition extending beyond the joints. Hyperuricemia, the core risk factor for gout, is also an independent risk factor for cardiovascular disease (CVD), complications, and mortality. Multiple conditions that predispose to gout and hyperuricemia, including obesity, metabolic syndrome, type 2 diabetes, hypertension, and chronic kidney disease (CKD), also elevate the risk of atherosclerosis, the central contributor to CVD and the leading cause of mortality in Western societies. The association between gout and atherosclerosis highlights the need for deeper understanding of causal links between these conditions. Because evidence remains insufficient to support urate-lowering therapies for improving cardiovascular outcomes, attention has shifted to other mechanisms connecting gout and atherosclerosis. Given the lack of convincing data for clinically significant monosodium urate crystal (MSUc) deposition in atherosclerotic plaques, this review focuses on the hypothesis that expansion of local articular to systemic inflammation, driven by macrophage activation by MSUc, is the primary mechanism accelerating atherosclerosis in gout. Mechanistically, we explore how epigenetic regulators normally restrain MSU-induced local inflammation, thereby protecting against atherosclerosis. We further discuss how aging-related somatic mutations in genes involved in clonal hematopoiesis of indeterminate potential (CHIP) disrupt this protection, resulting in heightened systemic inflammation and atherosclerosis in patients with gout.